STOCK TITAN

Baxter International Inc. - BAX STOCK NEWS

Welcome to our dedicated page for Baxter International news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter International stock.

Baxter International Inc. (NYSE: BAX) is a global healthcare company dedicated to providing essential renal and hospital products. With a comprehensive portfolio that includes home, acute, and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation, Baxter plays a critical role in expanding access to healthcare worldwide.

Baxter's recent acquisition of Hillrom in late 2021 has significantly enhanced its hospital-focused offerings. This acquisition brought basic equipment like hospital beds under Baxter’s umbrella, along with advanced digital solutions such as smart beds and the Voalte medical communications app. These additions complement Baxter’s legacy operations, which focus on products for patients with acute and chronic kidney failure. Notably, Baxter plans to spin off its renal care segment by mid-2024.

Additionally, Baxter provides a variety of injectable therapies, including IV pumps, administrative sets, and nutritional products, as well as surgical sealants and hemostatic agents used in various care settings. The company’s extensive global footprint and the essential nature of its products and services underscore its commitment to advancing healthcare innovations and improving patient care in both emerging and developed markets.

Baxter’s financial condition remains robust, bolstered by its continuous innovation and strategic partnerships. The company’s employees worldwide are dedicated to building upon a rich heritage of medical breakthroughs, ensuring that Baxter continues to be at the forefront of healthcare advancements.

Rhea-AI Summary
Baxter International launches digital image capture capability for eye exams
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
Rhea-AI Summary
Baxter International appoints Joel Grade as CFO, effective Oct. 18, 2023. Brian Stevens transitions to prior role. Grade brings decades of experience from Sysco. Positive impact expected on growth, innovation, and value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
management
-
Rhea-AI Summary
Advent International and Warburg Pincus complete the acquisition of Baxter International's BioPharma Solutions business, which will now operate as Simtra BioPharma Solutions. Baxter received $4.25 billion in cash. Simtra will continue to offer contract manufacturing solutions and support services to the pharmaceutical and biotech industries. The company plans to expand its drug development offering and capacity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
Rhea-AI Summary
Baxter International Inc. to discuss Q3 2023 financial results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
conferences earnings
-
Rhea-AI Summary
Baxter International to present at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
conferences
-
Rhea-AI Summary
Advent International and Warburg Pincus select Franco Negron as CEO of BioPharma Solutions following its divestiture from Baxter International Inc. The closing of the divestiture is expected to occur in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
Rhea-AI Summary
Baxter International Inc. to present at Wells Fargo Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences
-
Rhea-AI Summary
Baxter International appoints Stephen H. Rusckowski to its board of directors and announces the resignation of Michael Mahoney.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
management
-
Rhea-AI Summary
Baxter International Inc. (NYSE:BAX) reported a 3% increase in second-quarter revenues on a reported basis and 4% on a constant currency basis. The company also reported second-quarter U.S. GAAP earnings (loss) per share of ($0.28) and adjusted EPS of $0.66. Worldwide sales from continuing operations totaled approximately $3.71 billion, representing a 3% increase on a reported basis and 4% on a constant currency basis. The company is making progress on transformational actions announced at the start of 2023 to enhance strategic clarity, market responsiveness, and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
Rhea-AI Summary
Baxter International Inc. announces the name of its proposed spinoff, Vantive, for its Renal Care and Acute Therapies businesses. Vantive is expected to launch as an independent, publicly traded company by July 2024 or earlier.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none

FAQ

What is the current stock price of Baxter International (BAX)?

The current stock price of Baxter International (BAX) is $32.99 as of November 21, 2024.

What is the market cap of Baxter International (BAX)?

The market cap of Baxter International (BAX) is approximately 16.8B.

What does Baxter International Inc. specialize in?

Baxter specializes in essential renal and hospital products, including dialysis, sterile IV solutions, infusion systems, parenteral nutrition, biosurgery products, anesthetics, and pharmacy automation.

What was the impact of Baxter's acquisition of Hillrom?

The acquisition of Hillrom in late 2021 enhanced Baxter's hospital-focused offerings with additional equipment like hospital beds and digital solutions such as smart beds and the Voalte medical communications app.

What products does Baxter offer for kidney failure patients?

Baxter provides tools for patients with acute and chronic kidney failure, including home, acute, and in-center dialysis solutions.

What are some of Baxter's injectable therapies?

Baxter offers a range of injectable therapies, including IV pumps, administrative sets, and nutritional products.

What surgical products does Baxter provide?

Baxter provides surgical sealants and hemostatic agents used in various care settings.

What is Baxter's plan for its renal care segment?

Baxter plans to spin off its renal care segment by mid-2024.

How does Baxter contribute to global healthcare access?

Baxter’s global footprint and essential products play a key role in expanding access to healthcare in both emerging and developed countries.

How does Baxter ensure continuous innovation?

Baxter builds upon a rich heritage of medical breakthroughs and strategically partners to advance the next generation of healthcare innovations.

What are some of the digital solutions offered by Baxter?

Baxter offers digital solutions like smart beds and the Voalte medical communications app, acquired through Hillrom.

What is Baxter's commitment to patient care?

Baxter is committed to improving patient care by providing essential medical products, fostering healthcare innovations, and maintaining a robust financial condition.

Baxter International Inc.

NYSE:BAX

BAX Rankings

BAX Stock Data

16.78B
508.41M
0.38%
94.45%
2.25%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
DEERFIELD